Telo Genomics Corp. (TDSGF)
Telo Genomics Corp. is a biotechnology enterprise focused on developing and commercializing sophisticated predictive technologies. Their mission is to enable personalized treatment approaches for patients facing specific health challenges. The company's central offering is a telomere analysis platform, which provides both diagnostic insights and prognostic assessments. This platform leverages liquid biopsies and related innovations, with a particular emphasis on applications within oncology (cancer) and neurological diseases. A flagship product, Telo-MM, is a solution designed to equip healthcare professionals with crucial, actionable information for managing Multiple Myeloma, a type of blood cancer. Additionally, the company provides TeloView, a proprietary software platform used to precisely measure specific telomere features unique to each patient. Telo Genomics serves a diverse client base, including pathologists, clinicians, academic researchers, and drug developers. They have a collaborative agreement with the Mayo Clinic to conduct validation studies for their Telo-MM tests concerning multiple myeloma. Founded in 2014, the company was initially known as 3D Signatures Inc. before officially changing its name to Telo Genomics Corp. in April 2019. Its headquarters are located in Toronto, Canada.
Sector: Medical - Diagnostics & Research
Industry: Medical - Diagnostics & Research
Telo Genomics Corp.
- 0.0%
- 5.9K
- 1.63
Float 97.41M · FMP free float
The cost to borrow TDSGF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 100.0%
- 4.9K
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 5.9K sh |
| Oct 15, 2026 | 4.7K sh |
| Sep 30, 2026 | 13.3K sh |
| Sep 15, 2026 | 9.6K sh |
| Aug 31, 2026 | 9.7K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 13, 2026 | 4.9K sh |
| Oct 9, 2026 | 9.9K sh |
| Oct 8, 2026 | 14.1K sh |
| Oct 1, 2026 | 4.6K sh |
| Sep 30, 2026 | 4.6K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Oct 30, 2026 | 100.0% |
| Oct 29, 2026 | 100.0% |
| Oct 16, 2026 | 10.7% |
| Oct 13, 2026 | 100.0% |
| Oct 12, 2026 | 69.2% |
130 calendar days requested; 20 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for TDSGF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 5,917 TDSGF shares were sold short (0.01% of a 97.41M-share float, 1.63 days to cover).